Compare ResMed Inc. (RMD) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ResMed Inc. trades at $228.55 (market cap $31.89B), while YieldMax TSLA Option Income Strategy ETF trades at $22.64 (market cap $697.51M). The key difference: ResMed Inc. is far larger — about 45.7× YieldMax TSLA Option Income Strategy ETF's market cap, and ResMed Inc. pays a 1.16% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| RMD | TSLY | |
|---|---|---|
Market Cap | $31.89B | $697.51M |
Volume | 618,314 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $277.88 | $43.35 |
52-Week Low | $182.82 | $20.49 |
Typical Hold Time | 51 Days | 43 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
TSLY trades at $22.60, down 0.44% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.23, though recent analysis highlights concerns about capital erosion despite high yields. Technical indicators show support at $22 and resistance at $23, with neutral oscillators suggesting limited momentum.
While TSLY offers attractive income generation through its option income strategy, the fund faces structural limitations in capturing Tesla's upside potential. Recent downgrades to Hold reflect diminished return prospects amid Tesla's volatility changes. The primary risk remains the trade-off between high distributions and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
